Published • loading... • Updated
Seaport Reports Positive Dose Data From Trial of GlyphAgo for Anxiety - BioTuesdays
Summary by biotuesdays.com
3 Articles
3 Articles
Seaport reports positive dose data from trial of GlyphAgo for anxiety - BioTuesdays
Seaport Therapeutics (NASDAQ: SPTX) has announced positive data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. The trial, which included 174 participants, was conducted in multiple parts to evaluate the safety, tolerability, and PK of GlyphAgo and to compare the PK of GlyphAgo to agomelatin…
Coverage Details
Total News Sources3
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium